论文部分内容阅读
AIM:TO evaluate the association between X-ray cross- complementing gene 1 (XRCC1) genetic polymorphism Arg399GIn and gastric cancer risk by means of meta- analysis. METHODS:We searched PubMed and NCBI up to June 1,2008.A total of 16 clinical trials and reports were identified,but only 8 trials qualified under our selection criteria.Statistical analysis was performed with the software program Review Manage,version 4.2.8. RESULTS:Of the 8 case-control studies selected for this meta-analysis,a total of 1334 gastric cancer cases and 2194 controls were included.For Arg399Gln,the Gln/Gln genotype carriers did not have a decreased cancer risk compared with those individuals with the Arg/Arg genotype (OR=0.92,95% CI,0.71-1.19; P=0.51).Similarly,no associations were found in the recessive and dominant modeling (Gln/Gln vs Arg/Gln +Arg/Arg:OR=0.96;95% CI,0.77-1.19;P=0.70 and Gln/Gln+Arg/Gln vs Arg/Arg:OR=0.90,95% CI,0.77-1.05;P=0.18). CONCLUSION:No association is found between the XRCC1 polymorphism Arg399Gln and gastric cancer risk.
AIM: TO evaluate the association between X-ray cross- complementing gene 1 (XRCC1) genetic polymorphism Arg399GIn and gastric cancer risk by means of meta- analysis. METHODS: We searched PubMed and NCBI up to June 1,2008. A total of 16 clinical trials and reports were identified, but only 8 trials qualified under our selection criteria. Statistical analysis was performed with the software program Review Manage, version 4.2.8. RESULTS: Of the 8 case-control studies selected for this meta-analysis, a total of 1334 gastric cancer cases and 2194 controls were included. For Arg399Gln, the Gln / Gln genotype carriers did not have a decreased cancer risk compared with those individuals with the Arg / Arg genotype (OR = 0.92, 95% CI, 0.71-1.19 ; P = 0.51) .Similarly, no associations were found in the recessive and dominant modeling (Gln / Gln vs. Arg / Gln + Arg / Arg: OR = 0.96; 95% CI, 0.77-1.19; P = 0.70 and Gln / Gln + Arg / Gln vs. Arg / Arg: OR = 0.90, 95% CI, 0.77-1.05; P = 0.18). CONCLUSION: No association is found between the XRCC1 polymorp hism Arg399Gln and gastric cancer risk.